SG11201805363QA - Drug comprising aripiprazole and cilostazol - Google Patents

Drug comprising aripiprazole and cilostazol

Info

Publication number
SG11201805363QA
SG11201805363QA SG11201805363QA SG11201805363QA SG11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA SG 11201805363Q A SG11201805363Q A SG 11201805363QA
Authority
SG
Singapore
Prior art keywords
international
cilostazol
aripiprazole
busan
pct
Prior art date
Application number
SG11201805363QA
Other languages
English (en)
Inventor
Hwa Kyoung Shin
Byung Tae Choi
Ki Whan Hong
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of SG11201805363QA publication Critical patent/SG11201805363QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11201805363QA 2015-12-25 2016-12-22 Drug comprising aripiprazole and cilostazol SG11201805363QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015006489 2015-12-25
PCT/JP2016/088554 WO2017111123A1 (en) 2015-12-25 2016-12-22 Drug comprising aripiprazole and cilostazol

Publications (1)

Publication Number Publication Date
SG11201805363QA true SG11201805363QA (en) 2018-07-30

Family

ID=59090570

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805363QA SG11201805363QA (en) 2015-12-25 2016-12-22 Drug comprising aripiprazole and cilostazol

Country Status (14)

Country Link
US (1) US20190008854A1 (ko)
EP (1) EP3393476A1 (ko)
JP (1) JP2018538344A (ko)
KR (1) KR20180097652A (ko)
CN (1) CN108430474A (ko)
AU (1) AU2016375724A1 (ko)
BR (1) BR112018012903A2 (ko)
CA (1) CA3009309A1 (ko)
MX (1) MX2018007791A (ko)
PH (1) PH12018501315A1 (ko)
RU (1) RU2018127013A (ko)
SG (1) SG11201805363QA (ko)
TW (1) TW201729809A (ko)
WO (1) WO2017111123A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112107579A (zh) * 2019-06-21 2020-12-22 澳门大学 阿立哌唑在抗衰老中的应用
JPWO2021230131A1 (ko) * 2020-05-11 2021-11-18
CN114762688B (zh) * 2021-01-13 2024-07-05 南京宁丹新药技术有限公司 一种含有西洛他唑的组合物在脑血管病中的应用
WO2022270663A1 (ko) * 2021-06-23 2022-12-29 동아에스티 주식회사 도네페질, 실로스타졸 및 아리피프라졸을 포함하는 치매, 인지장애 또는 혈관성 우울증의 예방, 개선 또는 치료용 약학적 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5715303B2 (ja) * 2012-06-15 2015-05-07 公益財団法人先端医療振興財団 軽度認知障害の予防および/または治療剤

Also Published As

Publication number Publication date
RU2018127013A (ru) 2020-01-27
WO2017111123A1 (en) 2017-06-29
TW201729809A (zh) 2017-09-01
AU2016375724A1 (en) 2018-07-12
CN108430474A (zh) 2018-08-21
BR112018012903A2 (pt) 2018-12-11
CA3009309A1 (en) 2017-06-29
EP3393476A1 (en) 2018-10-31
PH12018501315A1 (en) 2019-02-18
US20190008854A1 (en) 2019-01-10
JP2018538344A (ja) 2018-12-27
MX2018007791A (es) 2018-11-09
KR20180097652A (ko) 2018-08-31

Similar Documents

Publication Publication Date Title
SG11201907034PA (en) Methods of treating influenza
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809126RA (en) Aromatic sulfonamide derivatives
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201408271VA (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201805363QA (en) Drug comprising aripiprazole and cilostazol
SG11201403402VA (en) Compounds
SG11201805368YA (en) Anthelmintic depsipeptide compounds
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201809341PA (en) Mobile robot
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201804587QA (en) Isoindole compounds
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201807835RA (en) An injector with reduced break loose force
SG11201810934TA (en) Microparticles comprising a sulphur-containing compound